Fmr LLC Boosts Stake in Emergent BioSolutions Inc. (NYSE:EBS)

Fmr LLC increased its stake in Emergent BioSolutions Inc. (NYSE:EBS) by 12.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 129,099 shares of the biopharmaceutical company’s stock after purchasing an additional 14,446 shares during the quarter. Fmr LLC owned approximately 0.24% of Emergent BioSolutions worth $1,078,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Landscape Capital Management L.L.C. bought a new position in shares of Emergent BioSolutions in the third quarter worth about $141,000. Entropy Technologies LP purchased a new stake in Emergent BioSolutions in the 3rd quarter worth approximately $155,000. PFG Investments LLC bought a new stake in Emergent BioSolutions during the 3rd quarter worth approximately $228,000. Assenagon Asset Management S.A. lifted its holdings in Emergent BioSolutions by 74.5% during the third quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company’s stock valued at $6,192,000 after purchasing an additional 316,700 shares in the last quarter. Finally, SeaCrest Wealth Management LLC boosted its position in shares of Emergent BioSolutions by 3.2% in the third quarter. SeaCrest Wealth Management LLC now owns 118,700 shares of the biopharmaceutical company’s stock worth $991,000 after purchasing an additional 3,705 shares during the period. 78.40% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently commented on EBS. StockNews.com upgraded shares of Emergent BioSolutions from a “hold” rating to a “buy” rating in a research report on Thursday, December 12th. Benchmark raised their price target on Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Finally, Rodman & Renshaw reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Emergent BioSolutions in a research note on Friday, September 13th.

Emergent BioSolutions Price Performance

EBS stock opened at $8.87 on Tuesday. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The company’s fifty day moving average price is $9.35 and its 200-day moving average price is $8.73. Emergent BioSolutions Inc. has a one year low of $1.42 and a one year high of $15.10. The company has a market capitalization of $480.61 million, a PE ratio of -2.16 and a beta of 1.59.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.